Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2008031051) CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF HUMAN SERUM PROTEIN BIOMARKERS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

WHAT IS CLAIMED IS:

1. A method of detecting fibrosis, comprising:
a) determining the level of at least one HF-AS SOCIATED polypeptide in a biological sample obtained from a patient; and
b) comparing said level of (a) to a control level of said HF-ASSOCIATED polypeptide in order to determine a positive or negative diagnosis of said fibrosis.
2. The method of claim 1, wherein said fibrosis is hepatic fibrosis.
3. The method of claim 1 , wherein said polypeptide is selected from the group consisting of: inter-α-trypsin inhibitor heavy chain H4 fragments, αl antichymotrypsin, apolipoprotein Ll (Apo Ll), prealbumin, albumin, isoforms of CD5 antigen like protein (CD5L), β2 glycoprotein I (β2GPI), α2 macroglobulin (a2M) and immunoglobulin components, αl, α2 and β chains of haptoglobin, complement components (C3, C4 and factor H-related protein 1), adiponectin, ApoE, prothrombin, clusterin, and angiotensinogen.
4. The method of claim 1, wherein the fibrosis includes differential regulation of HF-AS SOCIATED polypeptides.
5. The method of claim 1, wherein the biological sample is serum.
6. A method for scaling the severity of fibrosis comprising:
a) determining the level of at least one HF-AS SOCIATED polypeptide in a biological sample obtained from a patient; and
b) comparing said level of HF- ASSOCIATED polypeptides in said patient biological sample to the predetermined level of said HF -ASSOCIATED polypeptides in a population of patients ranging from no fibrosis to cirrhosis.
7. The method of claim 6, wherein said fibrosis is hepatic fibrosis.
8. The method of claim 6, wherein said polypeptide is selected from the group consisting of: inter-α-trypsin inhibitor heavy chain H4 fragments, αl antichymotrypsin, apolipoprotein Ll (Apo Ll), prealbumin, albumin, CD5 antigen like protein (CD5L), β2 glycoprotein I (β2GPI), α2 macroglobulin (a2M) and immunoglobulin components, αl, α2 and β chains of haptoglobin and complement components (C 3, C4 and factor H-related protein 1).
9. The method of claim 6, wherein the fibrosis includes differential regulation of HF-AS SOCIATED polypeptides.
10. A kit useful for the prognosis of fibrosis, comprising a HF-ASSOCIATED agent wherein the agent specifically detects HF-ASSOCIATED polypeptides.
11. The kit of claim 10, wherein said agent is an antibody or functional equivalent thereof that binds HF-ASSOCIATED polypeptides.
12. The kit of claim 11 , wherein said antibodies are used to perform an ELISA assay.
13. A method for detecting a HF-ASSOCIATED polypeptide comprising a) isolating a biological sample from a patient with fibrosis,
b) isolating a biological sample from a patient without fibrosis, c) analyzing the samples from a) and b) using 2D-P AGE,
d) comparing the 2D-P AGE results to identify polypeptides with differential expression between patients with and without fibrosis.
14. A method of determining the prognosis of fibrosis, comprising:
a) determining the level of a HF-ASSOCIATED polypeptide in a biological sample obtained from a patient; and
b) comparing said level of (a) to a control level of said HF-ASSOCIATED polypeptide in order to determine a positive or negative diagnosis of said fibrosis.
15. The method of claim 14, wherein said fibrosis is hepatic fibrosis.
16. The method of claim 14, wherein said polypeptide is selected from the group consisting of: inter-α-trypsin inhibitor heavy chain H4 fragments, αl antichymotrypsin, apolipoprotein Ll (Apo Ll), prealbumin, albumin, CD5 antigen like protein (CD5L), β2 glycoprotein I (β2GPI), α2 macroglobulin (a2M) and immunoglobulin components, αl, α2 and β chains of haptoglobin and complement components (C 3, C4 and factor H-related protein 1).

17. The method of claim 14, wherein the fϊbrsis is characterized by differential regulation of HF- ASSOCIATED polypeptides.